US20120135084A1 - Use of Deuterium Oxide for Treating Viral Diseases of the Eye - Google Patents

Use of Deuterium Oxide for Treating Viral Diseases of the Eye Download PDF

Info

Publication number
US20120135084A1
US20120135084A1 US13/143,596 US201013143596A US2012135084A1 US 20120135084 A1 US20120135084 A1 US 20120135084A1 US 201013143596 A US201013143596 A US 201013143596A US 2012135084 A1 US2012135084 A1 US 2012135084A1
Authority
US
United States
Prior art keywords
virus
eye
cell culture
viruses
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/143,596
Other languages
English (en)
Inventor
Thomas Bayerl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D2 Bioscience Group Ltd
Original Assignee
D2 Bioscience Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D2 Bioscience Group Ltd filed Critical D2 Bioscience Group Ltd
Assigned to D2 BIOSCIENCE GROUP LTD. reassignment D2 BIOSCIENCE GROUP LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYERL, THOMAS
Publication of US20120135084A1 publication Critical patent/US20120135084A1/en
Assigned to D2 BIOSCIENCE GROUP LTD. reassignment D2 BIOSCIENCE GROUP LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYERL, THOMAS MARIA, DR.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of deuterium dioxide (D2O) for the prevention and/or treatment of virus-based diseases of the eye.
  • D2O deuterium dioxide
  • virus infections Diseases caused by viruses (virus infections) occur worldwide and represent a serious problem in medicine, in particular because of the high variability, adaptability, and mutation rate of viruses.
  • Viruses are small particles of approx. 15 to 400 nm in diameter, which are not capable of replicating themselves alone but require a host cell for this.
  • infect animals invertebrates and vertebrates
  • plants bacteria or algae
  • fungi fungi
  • protozoa a distinction is made between viruses that infect animals (invertebrates and vertebrates), plants, bacteria or algae, fungi, and protozoa.
  • Virus infections in general are characterized by a high reproduction rate of the viral particles in the affected host cells, which can be described by an exponential or power law.
  • the reproductive cycle of viruses occurs via the injection of their nucleic acid (viral RNA or viral DNA) into the host cell, in which the replication of the nucleic acid takes place by utilizing the replication apparatus of the host cell.
  • the lytic cycle active infection
  • the replication of the viral nucleic acid takes place in the cell nucleus of the host cell, and assembly of the new viral particles in the cytoplasm, after which the host cell is finally lysed (destroyed) and the viruses are released.
  • the viruses thus released infect other host cells.
  • the nucleic acid of the virus is integrated into the host cell genome, where it remains initially without destroying the host cell.
  • this lysogenic cycle can change into an aforementioned lytic cycle.
  • RNA viruses after infection therewith transcription of the RNA into DNA is necessary so that replication by the host cell can take place. This process takes place via reverse transcriptase, an enzyme which is encoded by viral genes and must first be synthesized in the host cell in order to transcribe the viral. RNA into viral DNA, which is then in turn replicated by the DNA polymerase of the host cell.
  • Viruses are capable of infecting a broad spectrum of cells, organs, and hosts. Each virus species infects specifically preferred cells, such as, for example, cells of the stomach, intestine, skin, and eyes. This leads to many so-called virus-based diseases.
  • Viruses that cause such virus-based diseases of the eye comprise in particular herpesviruses, such as herpes simplex virus 1, herpes simplex virus 2, Epstein-Barr virus, varicella zoster virus and cytomegalovirus, adenoviruses, influenza viruses, parainfluenza viruses, picornaviruses, such as rhinoviruses, coxsackie A virus, coxsackie B virus, and echoviruses, molluscum contagiosum virus (poxvirus), vaccinia viruses, mumps viruses, measles viruses, rubella viruses, polioviruses, rabies viruses, human immunodeficiency viruses, and Rift Valley fever virus, but they are not limited thereto.
  • herpesviruses such as herpes simplex virus 1, herpes simplex virus 2, Epstein-Barr virus, varicella zoster virus and cytomegalovirus
  • adenoviruses influenza viruses, parainfluenza viruses,
  • viruses are transmitted mostly by droplet and smear infections.
  • viruses first infect skin cells, such as epithelial cells, mucous and mucous membrane cells, of the eye, followed by intense reproduction of the virus in the host cell and death of the infected host cell.
  • the host reacts with an immune response which leads to various symptomatic clinical pictures.
  • Virus-based diseases of the eye include, for example, keratoconjunctivitis or conjunctivitis, especially epidemic keratoconjunctivitis, keratoconjunctivitis sicca, hemorrhagic conjunctivitis, follicular conjunctivitis, pharyngoconjunctival fever, blepharitis, blepharoconjunctivitis, herpes simplex blepharitis, herpes simplex keratitis, dendritic keratitis, interstitial keratitis, endotheliitis/disciform keratitis, (varicella) zoster ophthalmicus, ophthalmia neonatorum (neonatal conjunctivitis), molluscum contagiosum, canaliculitis, acute dacryoadenitis, dacryocystitis, acute retinal necrosis, episcleritis, scleriti
  • virus infections of the eye are similar for most viruses, with the exception of herpesviruses.
  • Some of the virus-based diseases of the eye can be caused by different viruses, and some are caused preferentially by a specific virus type (also virus species).
  • Keratoconjunctivitis e.g., is caused in most cases by adenoviruses, but can also be caused by other viruses, such as cytomegaloviruses.
  • the symptoms depend on the severity of the infection and the immune defenses of the host.
  • virus-based diseases of the eye are caused by infections by alphaherpesviruses (HSV-1, varicella zoster) and adenoviruses.
  • HSV-1 alphaherpesviruses
  • adenoviruses adenoviruses
  • Herpesviruses are common in vertebrates, particularly in mammals, and above all in humans, horses, pigs, cattle, goats, sheep, cats, and dogs.
  • Human herpesviruses (HHV) are differentiated into alpha-, beta-, and gammaherpesviruses (HHV-1 to HHV-8); viruses that can infect animals such as, for example, horses (equine herpesvirus), cattle (bovine herpesvirus), pigs (suid herpesvirus), cats (feline herpesvirus), dogs (canine herpesvirus), and poultry (gallid herpesvirus 1) also belong to the alpha and gamma viruses.
  • Alphaherpesviruses include herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), and varicella zoster virus (VZV).
  • HSV-1 herpes simplex virus 1
  • HSV-2 herpes simplex virus 2
  • VZV varicella zoster virus
  • Human alphaherpesviruses initially reproduce in the skin of the eye according to the lytic cycle, especially in epithelial cells, as well as in the oral and nasal mucosa (primary infection) and usually cause local damage, namely, in the form of a lesion, mostly of vesicles. Viruses released during reproduction further infect certain nerve cells (neurons) by attaching to receptors on nerve endings, which leads to ganglia of the facial nerve (trigeminus). The viral DNA penetrates into an axon, and is transported into the cytoplasm of the nerve cells and finally into the cell nucleus thereof.
  • nerve cells nerve cells
  • the incorporation of the viral DNA into the genome of the nerve cell occurs there and leads to a resting state (latency) in which only a few viral genes are expressed (lysogenic cycle).
  • Various external stimuli can lead to renewed activation of the virus, which ultimately results in the destruction (lysis) of the nerve cell.
  • the viral progeny arising during an activation are initially transported through the axon via the trigeminus to the site or region of the original infection and released at the nerve endings.
  • the viruses again infect epithelial cells and endothelial cells there and in advanced cases in infection of the eye also the corneal stroma (secondary infections).
  • the above-described primary HSV-1 infections of the eye affect primarily the skin of the eyelid, the conjunctiva, and the outer layers of the cornea.
  • the epithelium and mucous membranes of the lacrimal sacs, lacrimal canaliculi, and tear glands can be infected by the virus.
  • the described secondary infections by HSV-1 affect both superficial and deeper epithelial layers, e.g., such as deep layers of the cornea, the choroid, sclera, and other regions of the uvea.
  • the epithelial cells of these above-described epithelia are infected in particular by the virus.
  • HSV-1 infections of the eye can lead to various clinical pictures, in particular dacryocystitis, canaliculitis, dacryoadenitis, herpes simplex blepharitis, herpes simplex keratitis (dendritic keratitis, interstitial keratitis, endotheliitis), disciform keratitis, uveitis, acute necrotizing retinitis, scleritis, and follicular conjunctivitis.
  • the clinical pictures of the secondary infections are for the most part more serious than those of the primary infection.
  • Infections of the eye with varicella zoster viruses occur secondary to chickenpox infections.
  • Varicella zoster viruses also cause the disease zoster ophthalmicus (ocular herpes zoster). This disease usually begins with burning and pain on half of the face and forehead. Reddening of the skin and vesicle formation occur after a few days. In the area of the eye, swelling of the lids by vesicle formation on the eyelids, conjunctivitis, and keratitis may occur as a result of the virus infection.
  • Adenoviruses are DNA viruses, which infect both animals and humans. Of a total of 19 species, 6 are pathogenic to humans (human adenoviruses A-F). Human pathogenic types, causing virus-based diseases of the eye, are particularly the strains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 19, and 29.
  • Adenoviruses are notable for a high pH and temperature stability. They generally enter the body via the respiratory tract. The reproduction of the adenoviruses is not limited locally, however. They can reproduce according to the lytic replication cycle in epithelial cells of the pharynx, gastrointestinal tract, and eyes, primarily in the conjunctiva.
  • An infection of the eye with adenoviruses causes in particular keratoconjunctivitis, conjunctivitis, and severe keratitis, e.g., epidemic keratoconjunctivitis, as virus-based diseases of the eye.
  • Adenoviruses are the most common cause of virus-based conjunctivitis. Symptoms are tearing, painful eyes, sensitivity to light, and corneal erosions, which may last up to six weeks. Furthermore, adenoviruses may bring about pharyngoconjunctival fever.
  • the type and severity of the infection in this regard depends on the causative adenovirus type. For example, infections with adenoviruses 5, 8, and 19 lead to the most severe kerato-conjunctivitis of the eye. Infections with adenoviruses are highly contagious.
  • Antiviral active substances have been developed in past decades for the treatment of many virus infections, so-called virostatic agents, which are said to interfere in the reproductive cycle of the virus and to inhibit or block the viral infection of the host cell or the reproduction of the virus in the host cell.
  • virus-based diseases of the eye with antiviral active substances is currently possible solely in an infection by Herpesviridae, such as HSV-1, varicella zoster virus, and cytomegaloviruses, and influenza viruses (type A and type B).
  • Herpesviridae such as HSV-1, varicella zoster virus, and cytomegaloviruses, and influenza viruses (type A and type B).
  • HSV-1 herpesviridae
  • varicella zoster virus such as varicella zoster virus
  • cytomegaloviruses such as cytomegaloviruses
  • influenza viruses type A and type B
  • Herpes infections of the eye are treated with orally or topically administered virostatic agents, such as acyclovir (Zovirax®), valacyclovir (Valtrex®), (Goldblum D et al. Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. British Journal of Ophthalmologic 2008; Vol. 92:1201-1205) ganciclovir, trifluridine (Michael H G, Therapy of viral infections. Bull. N.Y. Acad. Med. 2008; Vol. 59, No. 8: 711-720), idoxuridine (Virieuxt®) (Michael H G, Therapy of viral infections.
  • virostatic agents such as acyclovir (Zovirax®), valacyclovir (Valtrex®), (Goldblum D et al. Comparison of oral antiviral therapy with valacyclovir or acyclovir
  • famciclovir (Famvir®)
  • cidofovir (Vistide®).
  • Famvir® famciclovir
  • Visvir® cidofovir
  • the virostatic agent to be administered depends, inter alia, on the herpesvirus species and the depth of the affected corneal layers in the eye.
  • Influenza A viruses and influenza B viruses are inhibited by neuraminidase inhibitors, such as zanamivir (Relenza®) and oseltamivir (Tamiflu®).
  • neuraminidase inhibitors such as zanamivir (Relenza®) and oseltamivir (Tamiflu®).
  • the enzyme neuraminidase helps the newly formed virus cells to bud off from the host cell, so that they can infect other cells. Viral reproduction is suppressed by the inhibition of neuraminidase and therefore further infection is stopped.
  • Neuraminidase inhibitors can also be used preventively to avoid a viral infection with influenza A and influenza B, particularly in the case of epidemics (Sugrue R J et al., Antiviral Drugs for the Control of Pandemic Influenza Virus. Annals Academy of Medicine, 2008, Vol. 37, 518-524).
  • M2 channel blockers (amantadine and rimantadine) are known, moreover, for influenza A virus. These prevent the “uncoating,” i.e., the release of viral nucleocapsids into the cytoplasm of the host cell and therefore the infection the host cell, as a result of which viral reproduction is terminated (Sugrue R J et al., Antiviral Drugs for the Control of Pandemic Influenza Virus. Annals Academy of Medicine, 2008, Vol. 37, 518-524).
  • neuraminidase inhibitors and M2 channel blockers because of their many adverse reactions are used only for the treatment of virus-based eye diseases, when a severe influenza infection has been diagnosed.
  • viruses such as, e.g., adenoviruses, mumps viruses, measles viruses, rubella viruses, Epstein-Barr virus, parainfluenza viruses, picornaviruses (rhinoviruses, coxsackie A virus, coxsackie B virus, echoviruses), molluscum contagiosum virus (poxvirus), vaccinia viruses, polioviruses, rabies viruses, human immunodeficiency viruses, and Rift Valley fever virus.
  • viruses such as, e.g., adenoviruses, mumps viruses, measles viruses, rubella viruses, Epstein-Barr virus, parainfluenza viruses, picornaviruses (rhinoviruses, coxsackie A virus, coxsackie B virus, echoviruses), molluscum contagiosum virus (poxvirus), vaccinia viruses, polioviruses, rabies viruses, human immunodeficiency
  • viruses such as, e.g., influenza viruses
  • influenza viruses are subject to constant mutations, so that new vaccines must be developed constantly.
  • the vaccinations are not effective in all vaccinated patients. Treatments for viral diseases accordingly cannot be replaced by vaccinations.
  • the object of the invention accordingly is to provide improved antiviral active substances for the prevention and/or treatment of virus-based diseases of the eye.
  • the invention relates in its first subject to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye and in its second subject to the use of deuterium oxide for the production of a drug for the prevention and/or treatment of virus-based diseases of the eye.
  • Another preferred embodiment of the invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby the virus-based diseases of the eye are epidemic keratoconjunctivitis, keratoconjunctivitis sicca, hemorrhagic conjunctivitis, follicular conjunctivitis, pharyngoconjunctival fever, blepharitis, blepharoconjunctivitis, herpes simplex blepharitis, herpes simplex keratitis, dendritic keratitis, interstitial keratitis, endotheliitis, disciform keratitis, (varicella) zoster ophthalmicus, ophthalmia neonatorum, molluscum contagiosum, canaliculitis, dacryoadenitis, acute dacryoadenitis, dacryocystitis, acute retinal necrosis, epi
  • a preferred embodiment of the invention therefore relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby this concerns a combination of two or more virus-based diseases of the eye.
  • these two or more virus-based diseases of the eye occur simultaneously or successively, in particular as a consequence of the first or one of the preceding disease(s).
  • Such a combination of two or more virus-based diseases of the eye in an especially preferred embodiment is rhinoconjunctivitis.
  • Virus-based diseases of the eye within the meaning of the invention should be taken to mean diseases of the eye caused by a virus through a virus infection.
  • the present invention discloses not only the treatment but also the prevention of virus-based diseases of the eye, as already defined above.
  • Virus-based diseases of the eye according to the invention should therefore also be taken to mean such diseases of the eye that are to be assigned to a preventive treatment of virus-based diseases of the eye within the meaning of the invention. These include, for example, diseases typically preceding a virus-based disease of the eye.
  • keratoconjunctivitis sicca and indications and/or subforms derived herefrom, such as e.g., superficial keratitis and filiform keratitis, which are accordingly expressly designated as a virus-based disease of the eye according to the invention.
  • a preferred novel use of D2O therefore relates to the administration of D2O in keratoconjunctivitis sicca.
  • the disclosure in the present invention under the generally used term “keratoconjunctivitis” includes all forms of keratoconjunctivitis as virus-based diseases of the eye.
  • eye within the meaning of the invention can include all types of tissue, particularly skin types and cell types that can be affected by a virus. According to the invention, these are also designated as “organs of the eye” or “organs” or “eye organs to be treated” or “organs to be treated.” These include both superficial and deeper skin layers, primarily the eyelid skin, conjunctiva, the outer layers of the cornea, and deeper layers the cornea, the choroid, sclera, and other regions of the uvea, the epithelia and mucous membranes of the eye, such as the lacrimal sacs, lacrimal canaliculi, and tear glands.
  • the epithelial cells of these above-described epithelia which are also included in the term “eye,” are infected in particular by the virus.
  • organs or organs of the eye represent regions of the eye accessible from the exterior. “Accessible from the exterior” within the meaning of the present invention means that the organs, particularly the mucous membranes thereof, can be reached by external application or administration of the active substance deuterium oxide (D2O) of the invention, i.e., not systemically.
  • D2O deuterium oxide
  • an “external” administration according to the invention can occur, for example, by means of a D2O-containing ophthalmic ointment (D2O ophthalmic ointment), D2O ophthalmic gel, D2O eye drops, or by irrigation of the corresponding organs or regions of the organs with D2O or by administration of liquid D2O or D2O gels or D2O hydrogels.
  • D2O ophthalmic ointment D2O ophthalmic ointment
  • D2O eye drops or by irrigation of the corresponding organs or regions of the organs with D2O or by administration of liquid D2O or D2O gels or D2O hydrogels.
  • Organs or regions of such organs which are to be defined according to the invention as “accessible from the exterior” are, e.g., the eyelid, conjunctiva, the outer layers of the cornea, and the epithelia and mucous membranes of the lacrimal sacs, lacrimal canaliculi, and tear glands.
  • Virus infection within the meaning of the invention should be taken to mean the active or passive penetration of a virus into an organism, such as a plant, animal, or human, and the reproduction thereof in this organism.
  • an organism such as a “host” according to the invention and includes vertebrates, in particular mammals, above all man, horses, pigs, cattle, goats, sheep, cats, and dogs.
  • the cells of such a host are designated as “host cells.”
  • An “organism to be treated” within the meaning of the present invention is such a host that either suffers from a virus-based disease of the eye and is therapeutically treated or is preventively treated with regard to such a disease, in this case man being a particularly preferred host.
  • An “organ to be treated” within the meaning of the invention is an organ of such an above-defined organism to be treated.
  • virus infection Infection by viruses
  • viral infection viral infection
  • a preferred embodiment of the invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby the virus is a virus from the family Herpesviridae, Poxviridae, Paramyxoviridae, Coronaviridae, Chordopoxviridae, Togaviridae, Orthomyxoviridae, Retroviridae, Adenoviridae, Picornaviridae, and/or Rhabdoviridae.
  • the virus is a virus from the genus Simplexvirus, Varicellovirus, Cytomegalovirus, Lymphocryptovirus, Chordopoxvirus, Rubivirus, Respirovirus, Morbillivirus, Rubulavirus, Adenovirus, Influenza A virus, Influenza B virus, Lentivirus, Mastadenovirus, Orthopoxvirus, Enterovirus, Rhinovirus, Lyssavirus, and/or Pneumovirus.
  • the virus is a virus of the species herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-Barr virus, Molluscipoxvirus, vaccinia virus, Rubivirus, German measles virus, rubella virus, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, measles virus, mumps virus, human immunodeficiency virus, human adenovirus A, human adenovirus B, human adenovirus C, human adenovirus D, human adenovirus E, human adenovirus F, poliovirus, echovirus, Coxsackie A virus, Coxsackie B virus, rhinovirus, rabies virus, respiratory syncytial virus, and/or Rift Valley fever virus.
  • HSV-1 herpes simplex virus 1
  • HSV-2
  • virus type and “virus species” are used synonymously.
  • prevention and/or treatment refer to any measure suitable for treating a virus-based disease of the eye which either represents a preventive treatment of such an emergent disease or of emergent symptoms thereof (prevention) or the treatment of the disease after onset and/or the avoidance of renewed onset of such a disease, for example, after a completed treatment period (therapy).
  • an effective prevention and/or treatment of a virus-based disease of the eye occurs in particular by topical or systemic administration of a pharmaceutical agent or an antiviral agent.
  • topical or “topical application” or “topical administration” should be taken to mean that a pharmaceutical or antiviral agent, according to the invention D2O, in contrast to systemic uptake, is taken up not into the bloodstream of the organism to be treated, but is only applied, placed, or introduced locally, especially superficially, onto/into an eye organ to be treated, particularly onto/into the epithelial cells or mucous membrane thereof, preferably as a formulation in the form of drops, i.e., in liquid form, such as, for example, as an eye rinse or eye drops, or a hydrogel, gel, ointment, or cream.
  • a pharmaceutical or antiviral agent according to the invention D2O, in contrast to systemic uptake, is taken up not into the bloodstream of the organism to be treated, but is only applied, placed, or introduced locally, especially superficially, onto/into an eye organ to be treated, particularly onto/into the epithelial cells or mucous membrane thereof, preferably as a formulation in the form of drops,
  • systemic administration should be taken to mean that a pharmaceutical or antiviral agent is taken up in the bloodstream of the organism to be treated.
  • topical administration of a pharmaceutical or antiviral agent has fewer adverse reactions than systemic administration, because with topical administration high active substance concentrations are only locally reached, i.e., in a defined and limited region of the organ, to be treated, of an organism, and the whole organism, more precisely its bloodstream, is not exposed to the active substance as is the case with systemic administration.
  • Such a pharmaceutical agent or antiviral agent, administered topically for the prevention and/or treatment of a virus-based disease of the eye should have at least one, preferably several, of the following properties:
  • D2O deuterium oxide
  • deuterium oxide is an effective antiviral agent with potential long-term action and is suitable for short-term, long-term, and repeated treatments of virus-based diseases of the eye.
  • deuterium oxide also referred to as D2O below, is a pharmaceutical or antiviral agent.
  • the term “pharmaceutical agent” is understood to be any inorganic or organic molecule, substance, or compound that has a pharmacological action.
  • pharmaceutical agent is used herein synonymously with the term “drug.”
  • pharmaceutical agent also include antiviral agent, including D2O.
  • antiviral agent defines an active agent that is administered for treating virus-based diseases and in particular virus-based diseases of the eye.
  • such an antiviral agent is suitable for inhibiting or blocking the viral infection of the host cell and/or the replication of viral nucleic acid in the host cell and/or the reproduction of the virus. If an antiviral agent blocks or inhibits viral reproduction, the term “virostatic agent” is also used.
  • pharmaceutical agent and “antiviral agent” are used synonymously within the meaning of the invention.
  • cells are vertebrate cells, in particular mammalian cells and above all human cells (cells of humans), namely, skin cells, above all epithelial cells, mucosal cells, and mucous membrane cells.
  • host cells are cells that have been infected or can be infected by a virus.
  • the defined cells and host cells of the invention are those of the eye.
  • D2O The properties of D2O and the use thereof of the invention as an antiviral agent for the prevention and/or treatment of virus-based diseases of the eye are explained hereafter:
  • Deuterium oxide (D2O) and water (H2O) differ physically in the substitution of the hydrogen atoms of H2O by deuterium atoms, whereby D2O has an approx. 10% higher density and approx. 25% higher viscosity.
  • the melting and boiling points of D2O are higher than for H2O.
  • a detailed comparison of the properties is given in the Handbook of Chemistry and Physics, Section 6 (Handbook of Chemistry and Physics, David R. Lide, Editor, 79 th edition, 1998, CRC Press, Boca Raton, USA).
  • hydratation (also called hydration) should be taken to mean the deposition of D2O molecules, instead of or in addition to H2O molecules, onto a given surface, namely, the eye organ to be treated.
  • a hydratation within the meaning of the invention can also be called D2O hydratation.
  • degree of hydratation or “hydratation level” is the time-averaged number of D2O molecules maximally binding via H bridges to a given surface, namely, the eye organs to be treated, instead of or in addition to H2O molecules.
  • degree of hydratation or hydratation level can also be called the degree of D2O hydratation or D2O hydratation level.
  • “Sustainability of the hydratation” in this case should be taken to mean the activation energy for the detachment of a D2O molecule or H2O molecule, bound by H bridges, from a surface, namely, the eye organ to be treated, a higher activation energy meaning higher sustainability.
  • the sustainability of the hydratation within the meaning of the invention can also be called the sustainability of the D2O hydratation.
  • Mucous membranes defined as organs (to be treated) of the eye according to the invention, are examples of particularly strongly hydrated membrane surfaces, in which the number of the H bridge bonding possibilities is greatly increased compared with other membranes (e.g., the skin surface) owing to the presence of glycolipids and glycoproteins.
  • a slight increase in hydratation and/or the sustainability of hydratation has especially significant consequences which act, advantageously on the use of D2O according to the invention.
  • a cell takes up different quantities of H2O depending on the level of its specific metabolic activity.
  • a cell that is infected by a virus, a so-called host cell, and in which reproduction of the virus takes place has a far higher metabolic activity than an uninfected cell of the same cell type in the surrounding region. The reason for this is that the host cell is bringing about not only its own replication, but also the replication of the virus. Because an increased metabolic activity of cells correlates with an increased water uptake, virus-infected host cells take up markedly more water (H2O) than uninfected cells. Because of the similar physical properties of H2O and D2O, D2O is taken up by cells parallel to H2O (if D2O and H2O are available) or instead of H2O (if only D2O is available).
  • enzymatic reactions in a cell can be altered by D2O at a sufficient concentration.
  • cells, and virus-infected cells to an increased extent take up D2O parallel to or instead of H2O.
  • D2O is administered to a virus-infected cell at a “sufficient concentration” according to the invention, i.e., more than 20% based on the total water content of a cell, this results in a blockade or inhibition of enzymatic reactions in the host cell.
  • RNA viruses the enzymatic blocking or inhibition by D2O also occurs for the synthesis of the reverse transcriptase which, encoded by virus genes, must be synthesized first in the host cell to transcribe the viral RNA into viral DNA, which is then in turn replicated by the DNA polymerase of the host cell. Blocking or inhibition of certain enzymatic reactions of the host cell by D2O therefore also blocks or inhibits the replication and therefore also the subsequent reproduction (as defined above) of a virus after a virus infection.
  • Another important aspect of the invention that is based on the described elevated binding property of D2O is that when D2O is administered in sufficient concentration, i.e., more than 20%, based on the total water content of a cell, cell division is blocked or inhibited. This occurs most probably, in addition to the stated blocking or inhibition of DNA replication, by the blocking or inhibition of mitosis in the animal cell division cycle (Laissue J A et al., Survival of tumor - bearing mice exposed to heavy water or heavy water plus methotrexate. Cancer Research, 1982, Vol. 42(3): 1125-1129).
  • this has crucial importance for the latency state in virus-based diseases of the eye in which the viruses are present in the resting state (latency) during the lysogenic cycle described in greater detail above.
  • the viral genome is integrated into the host cell genome and transferred to the host cell progeny together with the host genome during division of the host cell. In a blocking or inhibition of cell division, such a transfer of the virus to new cells is prevented.
  • blocking or inhibition of viral reproduction thus occurs by the use of D2O for the prevention and/or treatment of virus-based diseases of the eye.
  • This blocking or inhibition of viral reproduction by D2O as an antiviral agent occurs according to the invention in particular by:
  • to block or “blocking” according to the invention should be taken to mean that the replication of viral nucleic acids (viral RNA or viral DNA), viral reproduction, and/or the cell division rate of host cells of the invention are retarded and/or decreased, preferably up to 6%, preferably up to 10%, preferably up to 15%, also preferably up to 20%, more preferably up to 25%, more preferably up to 30%, also more preferably up to 35%, also more preferably up to 40%, also more preferably up to 45%, also more preferably up to 50%, still more preferably up to approx. 55%, still more preferably up to approx.
  • inhibitor or “inhibition” according to the invention means that the replication of viral nucleic acids (viral RNA or viral DNA), viral reproduction, and/or the cell division rate of host cells of the invention are prevented, preferably up to 95%, still more preferably up to 98%, and most preferably up to 100% (and therefore completely), compared with the replication or reproduction rate of the virus or the host cell division rate without administration of D2O.
  • D2O has considerable advantages over known antiviral and virostatic agent for the treatment of virus-based diseases of the eye, namely, above all the following properties of D2O:
  • D2O is administered non-systemically.
  • An especially preferred embodiment of the invention is the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, the deuterium oxide being administered topically.
  • This type of topical administration occurs preferably in the form of drops, i.e., in liquid form, such as, for example, as eye drops (D2O eye drops) or as a rinse (D2O eye rinse), or in solid form as a cream (D2O cream), ointment (D2O ointment), gel (D2O gel), or hydrogel (D2O hydrogel).
  • Another especially preferred embodiment of the invention is the use of deuterium oxide, whereby the deuterium oxide hydrates the eye or the eye organs to be treated, particularly the mucous membranes of the eye.
  • locally preventive or therapeutically active D2O concentrations and a locally preventive or therapeutically active hydratation by D2O can be achieved and at the same time stresses on the system (i.e., the bloodstream) and the adverse effects on healthy tissue and organs of the eye that are not to be treated, as well as tissues of other surrounding or distant organs (such as, for example, the liver or kidneys), which could be caused by a high concentration of D2O of more than 20% D2O, based on the total water content of the cell, can be decreased or completely avoided.
  • transport of D2O into the system can be prevented or limited by means well-known in the state of the art.
  • these means are, inter alia, the selective manipulation of the osmotic gradients across the mucous membrane (i.e., between the systemic part and the mucous membrane surface) by decreasing the water potential of the administered D2O by means of substances suitable for altering said water potential, in particular physiologically acceptable salts, such as sodium chloride, water-soluble polymers, and other non-pharmaceutical substances.
  • D2O can be used alone as a pharmaceutical agent, more precisely as an antiviral or virostatic agent, or in combination with one or more other pharmaceutical agent(s) and/or one or more other non-pharmaceutical agent(s) (which can be used especially for optimizing the topical administration of D2O as a pharmaceutical agent onto mucous membranes).
  • a preferred embodiment of the present invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby D2O is used in combination with at least one additional pharmaceutical agent and/or at least one additional non-pharmaceutical agent.
  • Such a combination of D2O and at least one additional pharmaceutical agent and/or at least one additional non-pharmaceutical agent is referred to hereafter as a “novel combination.”
  • Another preferred embodiment of the present invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby D2O is used in combination with at least one additional pharmaceutical agent, which is selected from the group consisting of virostatic agents, proteins, peptides, nucleic acids, and immunosuppressant agent.
  • Virostatic agents block the activity of enzymes, for example, DNA polymerase, reverse transcriptase, or proteases, and thereby block or inhibit the replication of the virus or the processing of a synthesized long viral protein into smaller protein segments. Examples thereof are: amantadine and rimantadine.
  • the response of epithelial or skin tissue to the reproduction of viruses, particularly if inflammation is already present, can be improved and optimized by the addition of immunosuppressant active substances, for example, corticosteroids and/or other immunomodulators.
  • immunosuppressant active substances for example, corticosteroids and/or other immunomodulators.
  • Proteins that may be used according to the invention should be taken to mean proteins that interfere in a suitable manner in the infective, replication, or reproductive cycle of the virus in a host cell.
  • “in a suitable manner” means that the proteins block, preferably inhibit, the adsorption of the virus onto the host cell, the injection of viral nucleic acid into the host cell, the replication of the DNA of the host cell or of the viral nucleic acid, the processing of the viral nucleic acid, or assembly of the viral particles to a complete virus, or otherwise interfere in the reproductive cycle of the virus.
  • these are protease inhibitors, uncoating inhibitors, penetration inhibitors, reverse transcription inhibitors, and DNA polymerase inhibitors.
  • Peptides that may be used according to the invention should be taken to mean, for example, peptides that influence, in particular increase, the membrane permeability of the host cell membranes in a suitable manner. As a result, improved transport of D2O and optionally of the additional pharmaceutical or the non-pharmaceutical agents of the invention into the host cell can be achieved. An example of this is melittin.
  • peptides that may be used as taught by the invention should be taken to mean all those peptides with effects analogous to those described above for proteins.
  • a modification of the genetic information of the cells in the region of the site of action or a selective turning off (“gene silencing”) of certain genes, for example, of DNA polymerase, of cells in the region of the site of action, i.e., of the eye organ to be treated, and thereby a modification of the proteome can be achieved by the addition of nucleic acids, parallel to the antiviral or virostatic action of D2O.
  • Gene silencing can have the result, for example, that genes involved in DNA damage defense (for example, p53, BRCA1, BRCA2, ATM, and CHK2) are switched off and thereby the viruses whose reproduction has been impeded by D2O in the cells no longer revert to a latent stage even in the long term (after the end of the topical D2O administration), but are prevented in the long term from expressing viral DNA.
  • Methods for “gene silencing” are well known to the person skilled in the art and described, for example, in Mello C C. Conte D, “Revealing the world of RNA interference” in Nature 431, 338-342 (Sep. 16, 2004).
  • the nucleic acids are DNA, preferably oligonucleotides, sense or antisense DNA, natural or synthetic, cDNA, genomic DNA, naked DNA, single- or double-stranded DNA, or circular DNA, or RNA, preferably antisense RNA, RNAi, siRNA, or other RNA molecules suitable for interference, which are not restricted in their length.
  • concentration of additional pharmaceutical agents to be used as taught by the invention apart from D2O as a pharmaceutical agent based on the total solution of a novel combination is within the range of at least 10 ⁇ 8 M to at least 5 ⁇ 10 ⁇ 2 M, preferably of at least 10 ⁇ 7 M to 10 ⁇ 3 M, and most preferably of at least 10 ⁇ 6 M to at least 10 ⁇ 2 M.
  • An especially preferred concentration range is within the range of at least 10 ⁇ 9 M to at least 10 ⁇ 2 M.
  • a likewise preferred embodiment of the present invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eyes, whereby D2O is used in combination with at least one additional non-pharmaceutical agent, whereby the at least one additional non-pharmaceutical agent is selected from the group consisting of pharmaceutically acceptable inorganic or organic acids or bases, polymers, copolymers, block copolymers, monosaccharides, polysaccharides, ionic and nonionic surfactants, or lipids, as well as mixtures thereof, albumin, transferrin, and DNA repair proteins, such as kinase inhibitors.
  • non-pharmaceutical agent within the meaning of the invention refers to any pharmacologically acceptable and therapeutically useful molecule, substance, or compound that is not a pharmaceutical agent but is administered to an organism to be treated, preferably together with at least one pharmaceutical agent of the invention, for example, formulated in a formulation of the invention, in order to influence, in particular to improve, qualitative properties of the pharmaceutical agent(s).
  • the non-pharmaceutical agent exert no or no appreciable or at least no undesired pharmacological effect in regard to the intended prevention or treatment of virus-based diseases of the eye.
  • Suitable non-pharmaceutical agents are, for example, pharmacologically acceptable salts, for example, sodium chloride, flavoring agents, vitamins, e.g., vitamin A or vitamin E, tocopherols, or similar vitamins or provitamins occurring in the human body, antioxidants such as, for example, ascorbic acid, and stabilizers and/or preservatives to prolong the use and storage period of a pharmaceutical agent or a formulation of the invention and other conventional non-pharmaceutical agents or excipients and additives known to the person skilled in the art.
  • non-pharmaceutical agent preferred according to the invention, of a novel combination and the effect thereof and suitable concentrations are provided below, but this enumeration is only by way of example and the present invention is not limited thereto:
  • the physiological tolerance of D2O in cells of organs of the eye can be improved for non-virus-infected cells by addition of water-soluble excipients and additives, such as, e.g., pharmaceutically acceptable inorganic or organic acids, bases, salts, and/or buffer substances for adjusting the pH.
  • water-soluble excipients and additives such as, e.g., pharmaceutically acceptable inorganic or organic acids, bases, salts, and/or buffer substances for adjusting the pH.
  • preferred inorganic acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid, hydrochloric acid and sulfuric acid in particular being preferred.
  • Examples of especially suitable organic acids are selected from the group consisting of malic acid, tartaric acid, maleic acid, succinic acid, acetic acid, formic acid, and propionic acid and particularly preferably ascorbic acid, fumaric acid, and citric acid.
  • mixtures of the recited acids may also he used, in particular of acids that apart from their acidic properties also have other properties, e.g., use as antioxidants, such as, for example, citric acid or ascorbic acid.
  • Examples of pharmaceutically acceptable bases are alkali metal hydroxides, alkali metal carbonates, and alkali metal ions, preferably sodium.
  • Mixtures of said substances may be used in particular for the adjustment and buffering of the pH; especially preferred in this case are potassium hydrogen phosphate and dipotassium hydrogen phosphate. sodium hydrogen phosphate and disodium hydrogen phosphate, as well as citric acid and sodium citrate.
  • Preferred buffer substances within the meaning of the invention further are PBS, HEPES, TRIS, MOPS, and other physiologically acceptable buffer substances, in particular those with a pK value within the range of from 4.0 to 9.0.
  • the concentration of these substances based on the total solution of a novel combination, lies preferably within the range of micromolar to millimolar, particularly preferably within the range of 1-100 mM.
  • water-soluble, noncytotoxic molecules such as, e.g., certain polymers (e.g., but not limited thereto, dextran, polyethylene glycol, agarose, cellulose, acrylic acid, and hyaluronic acid), copolymers, and block copolymers
  • an additional delay (retardation) in the passage of D2O into the epithelial cells of the eye with topical administration and also from epithelial cells into the system (bloodstream) can be achieved owing to their high water-binding capacity.
  • the strength and direction of the osmotic gradient across the skin can be modified or improved and optimized by the ability of polymers to lower the chemical potential (water potential) of D2O.
  • the concentration of said substances based on the total solution, lies within the range of micromolar to molar, preferably within the range of 1-500 mM.
  • the osmotic conditions in the region of the topical D2O administration and the D2O transport and D2O retention in the epithelial cells of the eye can be modified or optimized by addition of water-soluble, non-polymeric molecules which modify the density and/or viscosity of D2O, for example, but not limited thereto, monosaccharides and polysaccharides, in particular glucose, sucrose, dextrose, maltose, starch, and cellulose.
  • the concentration of said substances, based on the total solution of a novel combination preferably lies within the range of millimolar to molar, particularly preferably within the range of 1.0 mM to 1.5 M.
  • the transport of D2O into the epithelial cells of the eye on topical administration and within these epithelial cells can be modified by addition of substances that modify the interfacial tension of D2O, for example, but not limited thereto, ionic and nonionic surfactants or lipids, in particular a mixture of surfactants and lipids.
  • concentration of said substances based on the total solution of a novel combination, preferably lies within the range of micromolar to millimolar, particularly preferably within the range of 0.05-500 mM.
  • An additional increase in the D2O transport rate of the molecules, surrounded by a D2O hydration shell, into the target cells of the eye can be achieved by addition of water-soluble molecules that are known to be taken up to a particular extent by metabolically especially active cells, such as, e.g., virus-infected cells, for example, albumin or transferrin.
  • active cells such as, e.g., virus-infected cells, for example, albumin or transferrin.
  • the concentration or dosage of D2O and optionally of the at least one additional pharmaceutical and/or non-pharmaceutical agent depends on various factors, for example, the nature of the treatment, nature of the disease, disease state of the patient (mammal), nature of the active substance, etc. Such parameters are known to the person skilled in the art and the determination of the specific dosages is subject to the know-how of the skilled person. Suitable concentration information is disclosed herein. Some exemplary information on suitable concentration ranges has already been given above but these are only intended as guide values.
  • the D2O usable as taught by the invention is preferably present as a liquid.
  • D2O is preferably present in a solution, preferably with H2O (water) as solvent, and is also described herein as “mixture of D2O and H2O” or “D2O/H2O” if water is included, or as a “D2O solution” or “pure D2O” if no water is included.
  • Pure D2O preferably contains D2O in a concentration range of 98.0 to 100%, preferably 98.5 to 99.9%, particularly preferably 99.7% based on the total water content of the solution.
  • a novel mixture of D2O and H2O preferably contains D2O within a concentration range of from 1 to 99%, preferably 5 to 95%, further preferably 10 to 90%, also preferably 15 to 80%, more preferably 20 to 70%, also more preferably 30 to 60%, and most preferably 40 to 50%, where this information refers to the total water content of the mixture of D2O and H2O.
  • the preparation of a D2O solution of the invention and analogously thereto of a novel combination is carried out, for example, by mixing of the components, in particular of D2O and optionally H2O, and optionally of the at least one additional pharmaceutical and/or non-pharmaceutical agent. Further, optionally a solvent can be added by mixing, as described below.
  • H2O or the at least one additional pharmaceutical and/or non-pharmaceutical agent or the solvent to D2O occurs preferably in the liquid state.
  • the preparation can be achieved by any suitable process.
  • D2O is used alone (i.e., not in combination with H2O or at least one additional pharmaceutical and/or non-pharmaceutical agent) and at a concentration of 100% or approx. 99.9%, based on the total volume of the solution (i.e., pure D2O), pure D2O is the D2O solution of the invention.
  • the at least one additional pharmaceutical or additional non-pharmaceutical agent is hound to D2O. “Bound” within the meaning of the present invention means that the pharmaceutical or non-pharmaceutical agent is hydratized by D2O.
  • D2O or the novel combination is contained in a suitable solvent.
  • a solvent according to the invention can be an inorganic or organic solvent. Suitable solvents of the present invention should preferably be physiologically well-tolerated by the organism (in particular mammal) to which the active substance with solvent is administered, i.e., trigger no adverse reactions, e.g., toxic adverse reactions.
  • An especially preferred solvent is distilled water.
  • ethanol-water mixtures here the percentage by mass of ethanol in these mixtures is preferably within the range between 5% and 99% ethanol, also preferably within the range of 10% to 96% ethanol, more preferably between 50% and 92%, and most preferably between 69% and 91% ethanol.
  • D2O or a novel combination or a novel mixture of D2O and H2O can be “preformulated,” for example, packaged in suitable means for the transport of pharmaceutical agent, so-called “drug delivery” systems, for example, in nanoparticles, vectors, preferably gene transfer vectors, viral or nonviral vectors, poly- or lipoplex vectors, liposomes, or hollow colloids (i.e., hollow spheres of colloidal size).
  • drug delivery for example, in nanoparticles, vectors, preferably gene transfer vectors, viral or nonviral vectors, poly- or lipoplex vectors, liposomes, or hollow colloids (i.e., hollow spheres of colloidal size).
  • Suitable further for transport are naked nucleic acids, in particular naked DNA.
  • Suitable vectors, liposomes, hollow colloids, or nanoparticles and processes for the introduction of substances into such vectors, liposomes, hollow colloids, or nanoparticles are generally well-known in the state of the art and described, for example, in Cryan S -A., Carrier - based Strategies for Targeting Protein and Peptide Drugs to the Lungs. AAPS Journal, 2005, 07(01): E20-E41, and Sambrook et al., Molecular Cloning A Laboratory Manual. Cold Spring Harbor Laboratory (1989) NY.
  • Polyethylenimine or cationic lipids such as, e.g., DOTAP can be used preferably as gene transfer vectors.
  • Liposomes may be used preferably for packaging cytostatic agents; a detailed description is given, for example, in Koshkina N V et al., Paclitacel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clinical Cancer Research, 2001, 7, 3258-3262.
  • Proteins as pharmaceutically active substances can be packaged preferably in biocompatible poly-lactic/glycolic acid polymers (PLGA) by means of supercritical liquids, emulsion processes, and spray drying.
  • PLGA poly-lactic/glycolic acid polymers
  • D2O is preferably administered topically. This occurs by application, placing, or introduction of D2O onto/into the epithelial cells or mucous membranes of the eye organ to be treated preferably in the form of drops, i.e., in liquid form, such as, for example, as drops, a rinse, or in solid form, for example, as a cream, ointment, gel, or hydrogel, or in the form of a formulation.
  • drops i.e., in liquid form, such as, for example, as drops, a rinse, or in solid form, for example, as a cream, ointment, gel, or hydrogel, or in the form of a formulation.
  • the nature and duration of the topical administration of D2O for the prevention and/or treatment of virus-based diseases of the eye and the concentration of D2O and optionally additional pharmaceutical and/or non-pharmaceutical agent depend on the location and accessibility of the eye organ to be treated, apart from the severity of the disease and the patient's condition.
  • a preferred embodiment of the invention relates to the use of deuterium oxide for the prevention and/or treatment of virus-based diseases of the eye, whereby D2O is administered as a formulation.
  • the formulation is administered topically by application to the eye organ to be treated, particularly to the epithelial cells or mucous membrane thereof.
  • a novel formulation is especially preferably a liquid, cream, ointment, gel, or a hydrogel.
  • a novel formulation is an eye rinse (D2O eye rinse), eye drops (D2O eye drops), an ophthalmic ointment (D2O ophthalmic ointment), an ophthalmic gel (D2O ophthalmic gel), or an ophthalmic hydrogel (D2O ophthalmic hydrogel).
  • Such a “liquid” or liquid formulation within the meaning of the invention comprises formulations of pure D2O, a mixture of D2O and H2O, and a novel combination, provided it is in the liquid state. It is preferably administered in the form of drops or as a rinse.
  • Novel formulations are suitable for the treatment of virus-based diseases of the eye. They are applied topically to the organ to be treated, in particular to the epithelial cells or mucous membranes thereof. To this end, they are preferably administered as a liquid, preferably as a rinse or drops, or as a cream, ointment, gel, or hydrogel:
  • an “ointment” is a drug preparation for external use comprising a base compound of spreadable material, such as vaseline, to which the actual pharmaceutical agents, such as D2O, and/or non-pharmaceutical agents are added, for example, by mixing.
  • a “cream” within the meaning of the present invention should be taken to mean an ointment of the invention, which may also contain other components, such as cosmetic agents, e.g., perfumes, colorants, and/or emulsifiers, e.g., lecithin.
  • cosmetic agents e.g., perfumes, colorants, and/or emulsifiers, e.g., lecithin.
  • a cream should also be taken to mean a lotion.
  • a “gel” within the meaning of the present invention is the solution of a macromolecular substance, e.g., agarose, acrylic acid, alginic acid, polysiloxanes, or acrylamide, whose concentration is so high that under suitable conditions and optionally with the addition of other substances (e.g., salts, acids, fillers, buffer substances) the dissolved macromolecules hind together into a sponge-like, three-dimensional skeleton with liquid within its void spaces.
  • a macromolecular substance e.g., agarose, acrylic acid, alginic acid, polysiloxanes, or acrylamide
  • other substances e.g., salts, acids, fillers, buffer substances
  • the viscosity lies between liquid and solid.
  • Such a liquid is preferably pure D2O or a novel mixture of D2O and H2O.
  • a “hydrogel” within the meaning of the invention is a gel that is characterized by an especially high water uptake capacity; within the meaning of the invention, it consists preferably 20-99%, more preferably 70-99%, and especially preferably 80-99% of water, but without exhibiting the rheological properties of a classic liquid.
  • the hydrogel is transparent/translucent and at the same time spreadable, without its morphology and integrity being detrimentally affected by the spreading of the gel.
  • a formulation usable according to the invention in particular of an ointment, cream, or gel, is described exemplarily in the examples. If such a formulation contains additional pharmaceutical and/or non-pharmaceutical agents, these are preferably added by mixing of the formulation. It may occur, however, by any standard method known in the state of the art. Such methods and also the concentrations to be selected of the components or substances to be used are known to the person skilled in the art.
  • concentrations of D2O in a formulation usable according to the invention preferably lie within the following ranges:
  • a formulation usable according to the invention contains further at least one inorganic or organic solvent.
  • the solvent is preferably selected from the group consisting of ethanol, water, and glycerol, as well as mixtures thereof.
  • FIG. 1 shows Table 1, which in turn shows the number of viruses in a type-1 cell culture of the cell line SV-40 (human corneal epithelial cell line), prepared according to Example 4, at the time 72 hours after infection for various viruses.
  • the viral count was determined by electron microscopy by counting and averaging from 20 non-lysed cells each in the treatment group and the control group.
  • FIG. 2 shows Table 2, which in turn shows the number of viruses in a modified type-1 cell culture of the cell line SV-40 (human corneal epithelial cell line), prepared according to Example 5, at the time 72 hours after infection for various viruses.
  • the viral count was determined by electron microscopy by counting and averaging from 20 non-lysed cells each in the treatment group and the control group.
  • FIG. 3 shows Table 3, which in turn shows the number of viruses in a type-2 cell culture of the cell line CCL 20.2 (human conjunctival epithelial cell line), prepared according to Example 6, at the time 72 hours after infection for various viruses.
  • the viral count was determined by electron microscopy by counting and averaging from 20 non-lysed cells each in the treatment group and the control group.
  • FIG. 4 shows Table 4, which in turn shows the results of the effectiveness of D2O hydrogel (treatment A), D2O eye drops (treatment B), and H2O hydrogel (control) for the treatment of ocular herpes in humans according to Example 25.
  • the “total symptom score” was averaged over the number of administrations per herpes incidence; for the “maximum size of the herpes,” “time between first symptoms and first administration,” “time to externally complete healing,” and “time to freedom from pain” averaging was performed over the total number of herpes incidences treated per group (treatment or control).
  • the provided errors are the standard deviations.
  • Deuterium oxide (D2O) with an enrichment of 98% or purified water (H2O) was combined with 160 mM NaCl and the mixture was adjusted to a pH of 7.0 with 20 mM phosphate buffer (sodium dihydrogen phosphate and disodium hydrogen phosphate).
  • the solutions were sterilized by processes that are the state of the art and stored until use under sterile conditions and protected from light.
  • Carbopol 980 manufactured by Noveon Inc., 9911 Brecksville Rd., Cleveland Ohio 44141-3247, USA
  • Carbopol 980 was dissolved in pure D2O (98% D enrichment) or in pure H2O by stirring and then titrated to a pH of 6.8 by pipetting with 10 M NaOH solution and buffered to this pH with 20 mM phosphate buffer (sodium dihydrogen phosphate and disodium hydrogen phosphate).
  • the colorless, transparent, and optically clear acrylic acid gels (Carbopol gels) (D2O Carbopol gel, H2O Carbopol gel), formed by NaOH addition as a result of crosslinking of the polyacrylic acid via its carboxyl groups with the alkaline hydroxy groups, were sterilized (autoclaved) and stored, aseptically packaged, at room temperature until further use, but for at least 24 hours.
  • D2O was added slowly to 50 g of Asche base cream (manufacturer: Asche Chiesi GmbH, Hamburg, Germany) with constant stirring at 40° C., until a percentage by weight of 38% D2O (based on the starting weight of the cream) in the homogenous mixture was achieved.
  • Asche base cream manufactured by Asche Chiesi GmbH, Hamburg, Germany
  • the cream was then cooled to room temperature and stored hermetically sealed.
  • Cells of the SV-40 cell line (human corneal epithelial cell line), prepared according to Araki-Sasaki K. et al. (“An SV40-Immortalized Human Corneal Epithelial Cell Line and Its Characterization,” Investigative Ophthalmology & Visual Science, March 1995, Vol. 36, No. 3), were seeded in 10 mm cell culture dishes at a cell density of 8 ⁇ 10 4 cells/cm 2 .
  • the medium used for this purpose was Dulbecco's Modified Eagle Medium, DMEM (Gibco/BRL, Life Technologies Inc., Grand Island, N.Y., USA) with 10% fetal calf serum, FCS (Hyclone, Logan, Utah, USA), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin (Sigma Chemical Co., St. Louis, Mo., USA). At a temperature of 37° C., the cells were grown to confluence at 95% atmospheric humidity and 5% CO 2 .
  • the cell culture medium On the day of infection of the cell culture with viruses, the cell culture medium was changed and the new medium (DMEM with 2% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin) contained the viruses at a concentration that corresponded to a multiplicity of infection (MOI) of 3. The probability that a cell is infected with at least one viral particle at this MOI was 95%. Infection and incubation occurred at a temperature and humidity analogous to those given above.
  • DMEM with 2% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin
  • Cells of the SV-40 cell line (human corneal epithelial cell line), prepared according to Araki-Sasaki K. et al. (“An SV40-Immortalized Human Corneal Epithelial Cell Line and Its Characterization,” Investigative Ophthalmology & Visual Science, March 1995, Vol. 36, No. 3), were seeded in 10 mm cell culture dishes at a cell density of 8 ⁇ 10 4 cells/cm 2 .
  • the medium used for this purpose was Dulbecco's Modified Eagle Medium, DMEM (Gibco/BRL, Life Technologies Inc., Grand Island, N.Y., USA) with 10% fetal calf serum, FCS (Hyclone, Logan, Utah, USA), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin (Sigma Chemical Co., St. Louis, Mo., USA). At a temperature of 37° C., the cells were grown to confluence at 95% atmospheric humidity and 5% CO 2 .
  • the cell culture medium was changed and the new medium (DMEM with 2% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin) was diluted with 30% D2O, 98% D-enrichment (treated culture), or diluted with 30% H2O (control culture).
  • the medium was replaced again by a medium of identical composition, which contained the viruses in concentrations that correspond to a multiplicity of infection of 3. Infection and incubation occurred at a temperature and humidity analogous to those given above.
  • Cells of the CCL 20.2 cell line (human conjunctival epithelial cell line) from the American Type Culture Collection (Manassas, Va., USA) were seeded in 10 mm cell culture dishes at a cell density of 8 ⁇ 10 4 cells/cm 2 .
  • the medium used for this purpose was Dulbecco's Modified Eagle Medium, DMEM (Gibco/BRL, Life Technologies Inc., Grand Island, N.Y., USA) with 10% fetal calf serum, FCS (Hyclone, Logan, Utah, USA), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin (Sigma Chemical Co., St. Louis, Mo., USA).
  • the cells were grown to confluence at 95% atmospheric humidity and 5% CO 2 .
  • the cell culture medium was changed and the new medium (DMEM with 2% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin) contained the viruses at a concentration corresponding to a multiplicity of infection (MOI) of 3.
  • MOI multiplicity of infection
  • the average number of viruses per cell was analyzed for the treated culture and the control culture.
  • the viral count was determined by transmission electron microscopy by standard fixation and staining methods (glutaraldehyde and osmium tetroxide). Before fixation, the cell culture medium was removed and the supernatant (after centrifugation at 20,000 g for 30 minutes) was stored for further analyses. In each case, 20 randomly selected, non-lysed cells from the treated and control culture were evaluated by electron microscopy in regard to their viral particle content.
  • cell culture dishes of cell culture type 1 according to Example 4 were infected with herpesviruses of type 1, HSV-1 (strain Maclntyre VR-539 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • HSV-1 strain Maclntyre VR-539 from the American Type Culture Collection, Manassas, Va., USA
  • cell culture dishes of cell culture type 1 according to Example 4 were infected with herpesviruses of the zoster type, varicella zoster (strain Ellen VR-586 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with human coronaviruses 229E. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with influenza A virus, type H1N1. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with influenza B virus/Hong Kong/5/72. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with human parainfluenza viruses 1, strain Washington 1957 (HPIV-1). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with HSRV, strain Long. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with human coxsackieviruses, type A1. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with human adenoviruses type 3, strain GZ1. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of cell culture type 1 were infected according to Example 4 with human enteroviruses type EV71, strain SHZH98. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • Example 4 6 cell culture dishes of cell culture type 1 according to Example 4 were infected with rhinoviruses (strain RV-16 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS. 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • rhinoviruses strain RV-16 from the American Type Culture Collection, Manassas, Va., USA. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS. 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin.
  • cell culture dishes of modified cell culture type 1 according to Example 5 were infected with herpesviruses type 2 (strain 734 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • herpesviruses type 2 strain 734 from the American Type Culture Collection, Manassas, Va., USA
  • cell culture dishes of cell culture type 2 according to Example 6 were infected with herpesviruses of type 1, HSV-1 (strain MacIntyre VR-539 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • HSV-1 strain MacIntyre VR-539 from the American Type Culture Collection, Manassas, Va., USA
  • cell culture dishes of cell culture type 2 according to Example 6 were infected with herpesviruses of type zoster, varicella zoster (strain Ellen, VR-586 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • cell culture dishes of modified cell culture type 2 according to Example 6 were infected with herpesviruses type 2 (strain 734 from the American Type Culture Collection, Manassas, Va., USA). 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • herpesviruses type 2 strain 734 from the American Type Culture Collection, Manassas, Va., USA. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/m
  • cell culture dishes of cell culture type 2 were infected according to Example 6 with human adenoviruses type 3, strain GZ1. 120 minutes after infection, the cell culture medium combined with the viruses was removed and replaced as follows with a diluted cell culture medium: in the treated group (3 cell culture dishes), by 30% D2O and 70% DMEM with 10% FCS, 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin. In the control group (3 cell culture dishes), the same amount of H2O was used instead of D2O for diluting the cell culture medium.
  • test subjects used antiviral or immunomodulating therapeutic agents a week before or during the test which was limited to 3 months.
  • the 33 test subjects were randomized to 3 groups (treatment groups A and B and a control) with 11 subjects in each.
  • Each test subject in treatment group A and the control group received a 20 g tube of a hydrogel prepared according to Example 2—treatment group A, a D2O hydrogel (prepared with 100% D2O), and the control group, an H2O hydrogel (prepared with 100% H2O) with the instruction to apply it to the affected mucous membrane site immediately upon the appearance of first ocular herpes symptoms.
  • Treatment group B received a 30 mL bottle of a D2O eye drop solution prepared according to Example 1. The application was to be repeated in all groups every 2 hours for the duration of 3 days during waking hours. The application amount was approx.
  • test subjects were instructed to keep an application log (patient diary) and to note each application in it and further also to enter for each application the following symptom details (symptom score), based on the previous application of the gel, on a scale from 1 (very limited/small) to 5 (very marked/large): a) itching b) pain, c) dryness, d) extent of the affected conjunctiva area.
  • symptom score a measure of the severity of the affected conjunctiva area.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
US13/143,596 2009-01-07 2010-01-06 Use of Deuterium Oxide for Treating Viral Diseases of the Eye Abandoned US20120135084A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009003942.2 2009-01-07
DE102009003942A DE102009003942A1 (de) 2009-01-07 2009-01-07 Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
PCT/IB2010/000029 WO2010079421A1 (de) 2009-01-07 2010-01-06 Verwendung von deuteriumoxid zur behandlung virus-basierter erkrankungen des auges

Publications (1)

Publication Number Publication Date
US20120135084A1 true US20120135084A1 (en) 2012-05-31

Family

ID=42041677

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/652,939 Abandoned US20100196285A1 (en) 2009-01-07 2010-01-06 Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract
US13/143,596 Abandoned US20120135084A1 (en) 2009-01-07 2010-01-06 Use of Deuterium Oxide for Treating Viral Diseases of the Eye
US13/478,808 Expired - Fee Related US8709496B2 (en) 2009-01-07 2012-05-23 Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/652,939 Abandoned US20100196285A1 (en) 2009-01-07 2010-01-06 Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/478,808 Expired - Fee Related US8709496B2 (en) 2009-01-07 2012-05-23 Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract

Country Status (4)

Country Link
US (3) US20100196285A1 (de)
EP (1) EP2385835B1 (de)
DE (1) DE102009003942A1 (de)
WO (1) WO2010079421A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
EP2110132B1 (de) * 2008-04-20 2014-01-22 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
TWI548874B (zh) * 2011-01-20 2016-09-11 國立台灣海洋大學 監測及紀錄病毒感染歷程及篩選疫苗之方法及系統
US20120276526A1 (en) * 2011-01-20 2012-11-01 National Taiwan Ocean University Method and system for monitoring and recording viral infection process and screening for agents that inhibit virus infection
DE102016125378A1 (de) * 2016-12-22 2018-06-28 Werner Schmidt Zusammensetzung zur Behandlung von Erkältungskrankheiten
US20230193972A1 (en) * 2021-12-21 2023-06-22 The Pullman Company Optimized mass cast bar pin for bushing assembly

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541195B2 (en) * 1996-04-10 2003-04-01 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20070141074A1 (en) * 2003-12-31 2007-06-21 Virologik Gmbh Agents for the inhibition of virus replication through regulation of protein folding
US20080249061A1 (en) * 2005-09-29 2008-10-09 Marc Wihsmann Photostable Pharmaceutical Composition Containing Brivudine for the Treatment of Herpetic Keratitis
US20090011022A1 (en) * 2007-07-05 2009-01-08 Bayerl Thomas M Use of deuterium oxide for treatment of virus-based diseases of the skin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019434A1 (de) 1980-05-21 1982-01-28 Horst Hanschmann Verfahren zur entkeimung von lebenden zellen
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5223269A (en) * 1989-08-31 1993-06-29 Andrejs Liepins Methods and composition for the treatment of hypertension
US5233269A (en) * 1990-04-13 1993-08-03 Varian Associates, Inc. Vacuum tube with an electron beam that is current and velocity-modulated
HU214593B (hu) * 1994-03-23 1998-06-29 HYD Kutató-Fejlesztő Kft. Kozmetikai, higiéniai, valamint szépség- és testápoló készítmények és eljárás azok előállítására
DE4427690A1 (de) 1994-08-04 1996-02-08 Bogdahn Ulrich Prof Deuterium enthaltende pharmazeutische Zusammensetzung als Zytostatikum oder Tumor-Therapeutikum
US6009876A (en) * 1997-05-20 2000-01-04 Yavitz; Edward Q. Method for modifying and reshaping collagen beneath the surface of skin
RU2083210C1 (ru) 1995-09-13 1997-07-10 Николаева Ирина Сергеевна Средство для профилактической, поддерживающей и восстановительной терапии развивающихся при старении и/или под воздействием патогенных факторов патологий, связанных с дистрофическим и дегенеративными изменениями органов и тканей
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6958390B1 (en) * 2000-06-14 2005-10-25 Stratagene California Compositions and kits for herpes simplex virus type 1 and 2 nucleic acid detection
US20040086453A1 (en) 2001-01-22 2004-05-06 Howes Randolph M. Compositions, methods, apparatuses, and systems for singlet oxygen delivery
UY27984A1 (es) * 2002-09-17 2004-04-30 Nippon Boehringer Ingelheim Co Composicion farmaceutica para el suministro por via topica de meloxicam
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
WO2006004759A2 (en) * 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
WO2006022460A1 (en) 2004-08-26 2006-03-02 Jong Yoon Bahk Composition and method of use on the deuterium oxide and deuterium oxide related products for prevention, suppression, and treatment of recurrent urothelial cancer and urothelical cancers including bladder cancer
US7659260B2 (en) * 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
DE102006049185A1 (de) * 2006-10-18 2008-04-24 Bayerl, Thomas M., Prof. Dr. Verwendung von Deuteriumdioxid zur Behandlung von hyperproliferativen Erkrankungen der Haut
EP2110132B1 (de) * 2008-04-20 2014-01-22 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541195B2 (en) * 1996-04-10 2003-04-01 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20070141074A1 (en) * 2003-12-31 2007-06-21 Virologik Gmbh Agents for the inhibition of virus replication through regulation of protein folding
US20080249061A1 (en) * 2005-09-29 2008-10-09 Marc Wihsmann Photostable Pharmaceutical Composition Containing Brivudine for the Treatment of Herpetic Keratitis
US20090011022A1 (en) * 2007-07-05 2009-01-08 Bayerl Thomas M Use of deuterium oxide for treatment of virus-based diseases of the skin
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"rhinoconjunctivitis" *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522292A (ja) * 2014-06-24 2017-08-10 シドネキシス,インク. 眼科用組成物
US9770447B2 (en) 2014-06-24 2017-09-26 Sydnexis, Inc. Ophthalmic composition
US10076515B2 (en) 2014-06-24 2018-09-18 Sydnexis, Inc. Ophthalmic Composition
US10201534B2 (en) 2014-06-24 2019-02-12 Sydnexis, Inc. Ophthalmic composition
US11896588B2 (en) 2014-06-24 2024-02-13 Sydnexis, Inc. Ophthalmic composition
US10842787B2 (en) 2014-06-24 2020-11-24 Sydnexis, Inc. Ophthalmic composition
US10864208B2 (en) 2014-06-24 2020-12-15 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11890277B2 (en) 2014-06-24 2024-02-06 Sydnexis, Inc. Ophthalmic composition
US11883390B2 (en) 2014-06-24 2024-01-30 Sydnexis, Inc. Ophthalmic composition
US11596625B2 (en) 2014-06-24 2023-03-07 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US10888557B2 (en) 2015-04-23 2021-01-12 Sydnexis, Inc. Ophthalmic composition
US10953002B2 (en) 2015-04-23 2021-03-23 Sydnexis, Inc. Ophthalmic composition
US10940145B2 (en) 2015-04-23 2021-03-09 Sydnexis, Inc. Ophthalmic composition
US10813923B1 (en) 2015-04-23 2020-10-27 Sydnexis, Inc. Ophthalmic composition
US11052095B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations

Also Published As

Publication number Publication date
US20120231088A1 (en) 2012-09-13
US8709496B2 (en) 2014-04-29
WO2010079421A1 (de) 2010-07-15
EP2385835A1 (de) 2011-11-16
EP2385835B1 (de) 2015-07-29
US20100196285A1 (en) 2010-08-05
DE102009003942A1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
US20120135084A1 (en) Use of Deuterium Oxide for Treating Viral Diseases of the Eye
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US9987300B2 (en) Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
JP6629216B2 (ja) 上気道感染症の治療のためのポリイノシン酸−ポリシチジル酸(ポリ(i:c))製剤
US20220265783A1 (en) Viral conjunctivitis treatment using ranpirnase and/or amphinase
US9919034B2 (en) Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
CN116056714A (zh) 预防冠状病毒及/或呼吸道融合病毒感染的方法
US11648300B1 (en) Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19
WO2019161761A1 (zh) 一种治疗疟疾的药物组合物
US8609147B2 (en) Use of deuterium oxide for treatment of herpes virus-based diseases of the skin
US20230233488A1 (en) Novel use of a modulator of glucosylceramide degradation for viral infections
CN116406273A (zh) 氮卓斯汀用作抗病毒治疗
TW202114690A (zh) 以費洛西洛韋(filociclovir)治療或預防眼部感染之組合物及方法
EP2385834B1 (de) Verwendung von deuteriumoxid zur behandlung virus-basierter erkrankungen des respirationstraktes
EP3678702A1 (de) Behandlung neurodegenerativer erkrankungen
WO2023235991A1 (en) Formulations and methods for protein encapsulation by spray freeze drying and microencapsulated compositions thereof
US20230111350A1 (en) Opthalmic Compositions for Treating Coronaviruses
US20220273594A1 (en) Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections
US20230310480A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + MOLNUPIRAVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
Wu et al. The antioxidant effect of tetrahedral framework nucleic acid‐based delivery of small activating RNA targeting DJ‐1 on retinal oxidative stress injury
WO2024096743A1 (en) Sars-cov-2 binding antibody
US20230310544A1 (en) ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG

Legal Events

Date Code Title Description
AS Assignment

Owner name: D2 BIOSCIENCE GROUP LTD., BERMUDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYERL, THOMAS;REEL/FRAME:027041/0571

Effective date: 20110818

AS Assignment

Owner name: D2 BIOSCIENCE GROUP LTD., BERMUDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYERL, THOMAS MARIA, DR.;REEL/FRAME:030261/0511

Effective date: 20080630

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION